Comparing the Molecular Pharmacological Properties of Existing β‐Blockers to Determine the Theoretically Most “Ideal” Anti‐Cancer β‐Blocker

Documenti analoghi

• A Comparison of the Molecular Pharmacological Properties of Current Short, Long, and Ultra‐Long‐Acting β2‐Agonists Used for Asthma and COPD
  di: Richard G. W. Proudman, et al.
  Pubblicazione: (2025)
• β‐Adrenergic Blockers Increase cAMP and Stimulate Insulin Secretion Through a PKA / RYR2 / TRPM5 Pathway in Pancreatic β‐Cells In Vitro
  di: Naoya Murao, et al.
  Pubblicazione: (2025)
• Association of Pharmacologic Markers of Anti‐Tumor Necrosis Factor‐α Activity and Etanercept Effectiveness in Juvenile Idiopathic Arthritis
  di: Mudassar I. Arain, et al.
  Pubblicazione: (2025)
• The blockade of the TGF‐β pathway alleviates abnormal glucose and lipid metabolism of lipodystrophy not obesity
  di: Wen‐Dong Xu, et al.
  Pubblicazione: (2024)
• Role of G protein‐coupled receptor kinases (GRKs) in β2‐adrenoceptor‐mediated glucose uptake
  di: Seungmin Ham, et al.
  Pubblicazione: (2024)